Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4–HspX

Niu, Hongxia; Hu, Lina; Li, Qing; Da, Zejiao; Wang, Bingxiang; Tang, Kangjian; Xin, Qi; Yu, Hao; Zhang, Ying; Wang, Yong; Ma, Xingming; Zhu, Bin

doi:10.1016/j.vaccine.2011.10.032

Cited by 61 publications

(51 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 dormancy antigens such as HspX 12 and 16 kDa heat shock protein, 12,39 and the Rpf-regulated gene Rv3407 40 as subunit vaccines against TB. We showed the three antigens (Rv3615c, Mtb10.4, Rv2660c) used in this study are all well-defined and effective.…”

Section: Discussionmentioning

confidence: 99%

“…Increasing the diversity of antigens in subunit vaccines may enhance their efficacy against M. tuberculosis and also ensure their recognition by T cells from diverse human populations. 12,14 It has been demonstrated that vaccines based on a combination of three antigens can induce levels of protection similar to or even better than those induced by BCG in mice. 43,44 We therefore decided to combine three antigens in our study to get powerful protection against TB.…”

Section: Discussionmentioning

confidence: 99%

“…9,10 For example, protein fusion vaccines constructed from two or three highly immunogenic, protective antigens, i.e.Ag85B and Esat6, were more efficacious than protein vaccines of the individual components alone. [11][12][13][14] Vaccines including combination of three plasmids encoding individual M. tuberculosis secreted proteins, 15 expression of multiple antigens with 2A or linker sequence, 16,17 and a synthetic scrambled antigen comprised of overlapping peptides from four M. tuberculosis proteins 18 also have been shown the great potency against TB in experimental model. About 170 M. tuberculosis antigens containing 800 human T cell epitopes have been identified in immune epitope databases.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection

Kong

Dong

Xiong

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection

Kong

Dong

Xiong

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The multi-antigenic, multistage subunit vaccine can be a very useful tool against complex microbes invading host cell by various pathways [26]. For Mtb, AID4 polyprotein, multistage subunit vaccine has been developed as a novel vaccine.…”

Section: Multistage Multi-antigenic Subunit Vaccinementioning

confidence: 99%

“…Another study studied Mtb10.4-HspX (MH) as multistage subunit fusion vaccine as a potential candidate for clinical use [26].…”

Section: Multistage Multi-antigenic Subunit Vaccinementioning

confidence: 99%

An Update on New Vaccines for Tuberculosis

Sumera

Inn

Barua

2016

Journal of Asian Scientific Research

View full text Add to dashboard Cite

Tuberculosis (TB) is one of the most common and deadly communicable diseases in the world, infectingapproximately one-third of the total human race. The number of drug-resistant TB cases are increasing. The spectrum of resistance varies from single to multidrug and from multidrug to total drug resistance varieties. Human Immunodeficiency Virus (HIV) infection is also responsible for the recent re-emergence of tuberculosis infection worldwide. When drugs are becoming ineffective against Mycobacterium tuberculosis, there is a need to focus more on preventive strategies. Though Bacillus Calmette-Guérin (BCG) vaccine is efficient in preventing miliary and meningeal tuberculosis in children, it is not effective against pulmonary tuberculosis. For prevention of pulmonary tuberculosis, development of new vaccines is the need of time. Several new vaccines are under clinical trials either to replace old BCG or act as a booster for the current BCG vaccine. New vaccines include live Contribution/ OriginalityThis study reviews current knowledge regarding the status of development of new vaccines for tuberculosis.

show abstract

Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines

Khademi

Taheri

Momtazi‐Borojeni

et al. 2018

Reviews of Physiology, Biochemistry and Pharmacology

View full text Add to dashboard Cite

The weakness of the BCG vaccine and its highly variable protective efficacy in controlling tuberculosis (TB) in different age groups as well as in different geographic areas has led to intense efforts towards the development and design of novel vaccines. Currently, there are several strategies to develop novel TB vaccines. Each strategy has its advantages and disadvantages. However, the most important of these strategies is the development of subunit vaccines. In recent years, the use of cationic liposome-based vaccines has been considered due to their capacity to elicit strong humoral and cellular immune responses against TB infections. In this review, we aim to evaluate the potential for cationic liposomes to be used as adjuvants/delivery systems for eliciting immune responses against TB subunit vaccines. The present review shows that cationic liposomes have extensive applications either as adjuvants or delivery systems, to promote immune responses against Mycobacterium tuberculosis (Mtb) subunit vaccines. To overcome several limitations of these particles, they were used in combination with other immunostimulatory factors such as TDB, MPL, TDM, and Poly I:C. Cationic liposomes can provide long-term storage of subunit TB vaccines at the injection site, confer strong electrostatic interactions with APCs, potentiate both humoral and cellular (CD4 and CD8) immune responses, and induce a strong memory response by the immune system. Therefore, cationic liposomes can increase the potential of different TB subunit vaccines by serving as adjuvants/delivery systems. These properties suggest the use of cationic liposomes to produce an efficient vaccine against TB infections.

show abstract

Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4–HspX

Cited by 61 publications

References 42 publications

A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection

A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection

An Update on New Vaccines for Tuberculosis

Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines

Contact Info

Product

Resources

About